Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial. - Post CCB; de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Leary A; Ottevanger PB; McCormack M; Khaw P; D'Amico R; Fyles A; et al. (The Lancet. Oncology, 2025)